3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag145 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Thomas Graillon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Aix Marseille University, APHM, INSERM, MMG (U1251), Hospital La Timone, 13005 Marseille, France. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Adenoma. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Purpose
The 2022 WHO classification states no histological grading exists to assess pituitary adenoma (PA) aggressiveness. The European Society of Endocrinology refers to the term “unusually rapid growth rate” when defining an aggressive PA. This study aimed to evaluate three-dimensional volume growth rate (3DVGR) in multiple PAs and correlate it with tumor progression and histopathology.
Methods
Patients with growing or proliferative PAs who underwent surgery were retrospectively selected. Gadolinium-enhanced 3D T1-weighted MRI was required.
Results
A total of 76 3DVGR measurements were performed on 50 nonproliferative and 25 proliferative PAs, with median 3DVGRs of 21.2%/year and 60.2%/year, respectively (P < .0001). ROC analysis (AUC 0.992, P < .001) defined three 3DVGR groups: <50%/year, ≥50%, and <80%/year, ≥80%/year with a median PFS of 99.0, 39.0, and 7.0 months, respectively. In tumors with 3DVGR <50%/year, proliferative status had no significant progression-free survival impact (P = .381). In contrast, proliferative tumors with 3DVGR ≥50%/year had worse outcomes than those with 3DVGR <50%/year (P < .001). In multivariate analysis, only 3DVGR ≥50%/year predicted early progression (P < .001), unlike proliferative status. Combining 3DVGR ≥80%/year or 50% ≤3DVGR < 80%/year with Ki67 ≥ 8% identified 12 PAs with a median PFS of 8.5 months vs 64 months in others.
Conclusion
PA proliferation may be categorized as: <10%/year: non and/or slowly progressive, 10-49%/year: slowly progressive, 50-79%/year: progressive, ≥80%/year: highly progressive. 3DVGR appears to be a valuable tool to evaluate PA proliferation alongside histology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Aix Marseille University, APHM, INSERM, MMG (U1251), Hospital La Timone, 13005 Marseille, France.
- Neuro-Oncology Department, Aix-Marseille University, APHM, CNRS, INP, Inst Neurophysiopathol, Hôpital La Timone, 13005 Marseille, France.
- Department of Pathology and Neuropathology, Aix-Marseille University, APHM, CNRS, INP, Inst Neurophysiopathol, Hôpital La Timone, 13005 Marseille, France.
- Department of Endocrinology, Aix Marseille University, APHM, INSERM U1251, MMG, Marmara Institute, Hôpital de la Conception, CRMR HYPO, 13005 Marseille, France.
- Laboratory of Molecular Biology GEnOPé, Aix Marseille University, APHM, INSERM, MMG (U1251), La Timone University Hospital, BIOGENOPOLE, 13005 Marseille, France.
- Department of Endocrinology, Aix Marseille University, APHM, INSERM, Clinical Investigation Centre U1409, La Conception University Hospital, 13005 Marseille, France.
ORCID-Profile: Thomas Graillon, Frederique Albarel, Pauline Romanet, Thierry Brue, Thomas Cuny
Zitieren
APA
Graillon, T., Tabouret, E., Appay, R., Albarel, F., Morange, I., Sahakian, N., Romanet, P., Barlier, A., Brue, T., Mansourt, A., Figarella-Branger, D., Castinetti, F., Cuny, T., & Dufour, H. (2026). 3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag145
Vancouver
Graillon T, Tabouret E, Appay R, Albarel F, Morange I, Sahakian N, et al. 3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag145
BibTeX
@article{Graillon2026,
author = {Graillon, Thomas and Tabouret, Emeline and Appay, Romain and Albarel, Frederique and Morange, Isabelle and Sahakian, Nicolas and Romanet, Pauline and Barlier, Anne and Brue, Thierry and Mansourt, Anis and Figarella-Branger, Dominique and Castinetti, Frédéric and Cuny, Thomas and Dufour, Henry},
title = {3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag145}
}
EUVIMED